Get the Stockscreener App
495.42
1.45%
7.08
Pre-market:
494.05
-1.37
-0.28%
Vertex Pharmaceuticals Inc stock is traded at $495.42, with a volume of 1.32M.
It is up +1.45% in the last 24 hours and up +9.32% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$488.34
Open:
$484.62
24h Volume:
1.32M
Relative Volume:
0.86
Market Cap:
$127.22B
Revenue:
$11.02B
Net Income/Loss:
$-535.60M
P/E Ratio:
-225.19
EPS:
-2.2
Net Cash Flow:
$-978.00M
1W Performance:
+0.77%
1M Performance:
+9.32%
6M Performance:
+3.50%
1Y Performance:
+20.12%
1-Day Range:
$483.09
$496.64
1-Week Range:
$479.78
$503.89
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.com - Defense World
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals EVP sells $1.62 million in stock - Investing.com
Vertex Pharmaceuticals EVP sells $1.6 million in stock - Investing.com
Vertex Pharmaceuticals Executives Sell Shares - TradingView
Vertex Pharmaceuticals CFO sells shares worth $1.65 million - Investing.com
Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio? - MSN
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report? - Yahoo Finance Australia
Where Will Vertex Pharmaceuticals Be in 10 Years? - sharewise
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA - PMLiVE
Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
If I Could Buy Only 1 Growth Stock, This Would Be It - The Motley Fool
UK MHRA approves Vertex’s Alyftrek for cystic fibrosis - Pharmaceutical Business Review
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jones Financial Companies Lllp - Defense World
UnitedHealth slots Vertex's non-opioid pain med at top of tiered formulary - FirstWord Pharma
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment - Yahoo Finance
Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary - Marketscreener.com
Vertex Announces UK Mhra Approval Of Alyftrek -March 07, 2025 at 11:32 am EST - Marketscreener.com
Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis - Marketscreener.com
(Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK - Marketscreener.com
UK Health Regulator Approves Vertex's Cystic Fibrosis Drug Alyftrek -March 07, 2025 at 07:46 am EST - Marketscreener.com
Vertex Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Zacks Research Has Optimistic Outlook of VRTX Q1 Earnings - Defense World
Vertex Non-Opioid Pain Drug Draws Bipartisan Support In House Hearing - Citeline News & Insights
Vertex’s new pain drug gets first coverage nod from major insurer - BioPharma Dive
Insider Sell Alert: Ourania Tatsis Sells Shares of Vertex Pharma - GuruFocus.com
Vertex’s Non-Opioid Pain Drug Gets Some UnitedHealth Coverage - Bloomberg
Vertex’s non-opioid pain drug gets some UnitedHealth coverage - The Boston Globe
Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine - MSN
Vertex Pharma stock drops on Journavx coverage (VRTX:NASDAQ) - Seeking Alpha
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher costBloomberg - Investing.com UK
Vertex Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating - Seeking Alpha
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector? - Nasdaq
Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Vertex Pharmaceuticals Stock: Is VRTX Outperforming The Healthcare Sector? - Barchart
Signs of hiring at Boston-area life sciences companies - The Business Journals
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations - BioSpace
Vertex's cystic fibrosis combination therapy Symdeko gains FDA approval - FirstWord Pharma
Insider Sell: Ourania Tatsis Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Acima Private Wealth LLC - MarketBeat
FourThought Financial Partners LLC Takes $279,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Mutual of America Capital Management LLC Has $13.25 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Flputnam Investment Management Co. Purchases 22,141 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
QRG Capital Management Inc. Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Illinois Municipal Retirement Fund Has $19.08 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.99%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):